BlackRock
TARO

BlackRock’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

BlackRock’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-615,581
Closed -$26.1M – 5379
2024
Q1 		$26.1M Sell
615,581
-7,402
-1% -$312K ﹤0.01% 2834
2023
Q4 		$26M Buy
622,983
+41,093
+7% +$1.51M ﹤0.01% 2854
2023
Q3 		$21.9M Buy
581,890
+52
+0% +$1.95K ﹤0.01% 2894
2023
Q2 		$22.1M Buy
581,838
+422,645
+265% +$13.3M ﹤0.01% 2984
2023
Q1 		$3.87M Sell
159,193
-13,668
-8% -$399K ﹤0.01% 3746
2022
Q4 		$5.02M Sell
172,861
-9,162
-5% -$272K ﹤0.01% 3723
2022
Q3 		$5.46M Buy
182,023
+14,244
+8% +$491K ﹤0.01% 3717
2022
Q2 		$6.07M Sell
167,779
-5,987
-3% -$228K ﹤0.01% 3731
2022
Q1 		$7.52M Sell
173,766
-3,904
-2% -$182K ﹤0.01% 3732
2021
Q4 		$8.9M Buy
177,670
+4,017
+2% +$225K ﹤0.01% 3749
2021
Q3 		$11M Buy
173,653
+5,323
+3% +$368K ﹤0.01% 3633
2021
Q2 		$12.1M Sell
168,330
-17,705
-10% -$1.3M ﹤0.01% 3578
2021
Q1 		$13.7M Buy
186,035
+35,262
+23% +$2.68M ﹤0.01% 3390
2020
Q4 		$11.1M Buy
150,773
+149,337
+10,400% +$9.6M ﹤0.01% 3304
2020
Q3 		$79K Buy
1,436
+634
+79% +$39.5K ﹤0.01% 4550
2020
Q2 		$53K Hold
802
– – ﹤0.01% 4574
2020
Q1 		$49K Sell
802
-341
-30% -$25.3K ﹤0.01% 4476
2019
Q4 		$101K Hold
1,143
– – ﹤0.01% 4448
2019
Q3 		$86K Hold
1,143
– – ﹤0.01% 4466
2019
Q2 		$98K Hold
1,143
– – ﹤0.01% 4475
2019
Q1 		$124K Sell
1,143
-3,465
-75% -$345K ﹤0.01% 4343
2018
Q4 		$390K Sell
4,608
-2,951
-39% -$284K ﹤0.01% 4116
2018
Q3 		$743K Buy
7,559
+3,338
+79% +$361K ﹤0.01% 4033
2018
Q2 		$489K Sell
4,221
-8,657
-67% -$951K ﹤0.01% 4107
2018
Q1 		$1.27M Buy
12,878
+3,849
+43% +$390K ﹤0.01% 3810
2017
Q4 		$946K Sell
9,029
-488,163
-98% -$53.6M ﹤0.01% 3911
2017
Q3 		$56M Sell
497,192
-5,882
-1% -$640K ﹤0.01% 2222
2017
Q2 		$56.4M Buy
503,074
+1,817
+0.4% +$205K ﹤0.01% 2166
2017
Q1 		$58.5M Buy
501,257
+487,435
+3,527% +$53.9M ﹤0.01% 2119
2016
Q4 		$1.46M Buy
13,822
+2,799
+25% +$293K ﹤0.01% 1352
2016
Q3 		$1.22M Buy
11,023
+1,112
+11% +$147K ﹤0.01% 1412
2016
Q2 		$1.44M Buy
9,911
+3,551
+56% +$504K ﹤0.01% 1290
2016
Q1 		$911K Buy
6,360
+2,057
+48% +$292K ﹤0.01% 1390
2015
Q4 		$665K Buy
4,303
+4,003
+1,334% +$584K ﹤0.01% 1451
2015
Q3 		$43K Buy
+300
New +$41.9K ﹤0.01% 1974

Other funds holding TARO

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $3.3B AUM 20.27% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
GCM
Gladius Capital Management Chicago, Illinois $2.24B AUM 23.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

BlackRock's TARO Position: Q2 2024 in Review

BlackRock sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2024, closing a stake of 615,581 shares — an estimated $26.1M sold.

BlackRock first reported a position in TARO in Q3 2015 and held it in 35 quarters. The position peaked at $58.5M in Q1 2017. 16 funds tracked by Wall St. Rank hold TARO as of Q2 2024.

  • BlackRock reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2024 after selling out during the quarter.
  • BlackRock sold 615,581 Taro Pharmaceutical Industries Ltd. shares in Q2 2024, an estimated $26.1M.
  • BlackRock first reported a position in Taro Pharmaceutical Industries Ltd. in Q3 2015 and held it in 35 quarters.
  • BlackRock's Taro Pharmaceutical Industries Ltd. position peaked at $58.5M in Q1 2017.
  • 16 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2024.

Based on BlackRock's 13F filing for Q2 2024, filed 13 Aug 2024.